Another monoclonal antibody used to treat MM, elotuzumab, targets the signaling lymphocytic activation molecule F7 (SLAMF7), which is highly expressed in plasma cells [1,278,279,280,281]. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.